Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Leuk Res ; 30(1): 118-9, 2006 Jan.
Article in English | MEDLINE | ID: mdl-15982732

ABSTRACT

We treated at our institution six patients with kidney transplantation and lymphoma. After the end of chemotherapy, re-introduction of therapeutic immune suppression was not necessary since, with a significant follow-up (median follow-up of 26 months, range 12-36), no patient had severe renal function deterioration. These preliminary data suggest that, after lymphoma treatment, immune suppression can be withhold at least for 2 years. Restoration of a functional immune system may contribute to decrease the rate of lymphoma recurrence, in line with the absence of lymphoma relapse in our six patients, who are all still alive and in complete remission.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Kidney Transplantation , Lymphoma, Non-Hodgkin/drug therapy , Adult , Aged , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Agents/administration & dosage , Cyclophosphamide/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Female , Follow-Up Studies , Humans , Immunosuppression Therapy , Lymphoma, Non-Hodgkin/complications , Male , Middle Aged , Prednisone/administration & dosage , Recurrence , Remission Induction , Rituximab , Vincristine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...